D-0880-2017 Class II Terminated
FDA drug recall D-0880-2017 was initiated by Forest Laboratories, LLC on May 18, 2017 and is designated Class II. Reason for recall: Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets The recall status is terminated (terminated Nov 15, 2018). Affected quantity: 40,621 blister packs.
Recall details
- Product Type
- Drugs
- Report Date
- Jun 7, 2017
- Initiation Date
- May 18, 2017
- Termination Date
- Nov 15, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 40,621 blister packs
Product description
Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06
Reason for recall
Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets
Distribution pattern
Nationwide
Code information
Lots W00733 and W00946, exp Apr 2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0880-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026